Nivolumab Immunotherapy–Related Skin Reactions Detected on 18F-FDG PET/CT in Renal Cell Cancer

alexandrossfakianakis shared this article with you from Inoreader Nivolumab Immunotherapy–Related Skin Reactions Detected on 18F-FDG PET/CT in Renal Cell Cancer Via Clinical Nuclear Medicine - Published Ahead-of-Print Nivolumab, a fully human immunoglobulin G4 anti–programmed cell death 1 antibody, provides a novel therapy option for patients with metastatic cancers. Immunotherapy agents have been associated with immune-related adverse events (irAEs), which may be detected on 18F-FDG PET/CT. Cutaneous toxicities are one of the most common irAEs in the form of maculopapular rash (eczema-like spongiotic dermatitis) and pruritus. These irAEs may lead to false-positive findings on PET/CT done during the treatment. One should be aware of the potential irAEs while interpreting PET/CT to avoid misinterpretation. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study

alexandrossfakianakis shared this article with you from Inoreader Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study Via Helicobacter Abstract Background Vonoprazan-amoxicillin (VA) dual therapy has been shown to achieve acceptable cure rates for treatment of Helicobacter pylori(H. pylori) in Japan. Its effectiveness in other regions is unknown. We aimed to explore the efficacy of VA dual therapy as first-line treatment for H. pyloriinfection in China. Methods This was a single center, prospective, randomized clinical pilot study conducted in China. Treatment naive H. pyloriinfected patients were randomized to receive either low- or high-dose amoxicillin-vonoprazan consisting of amoxicillin 1 g either b.i.d. or t.i.d plus VPZ 20 mg b.i.d for 7 or 10 days. 13C-urea breath tests were used to access the cure rate at least 4 weeks after treatment. Results Three hundred and twenty-three patients were assessed, and 119 subjects were randomized. The eradication rates of b.i.d. amoxicillin for 7 and 10 days, t.i.d. amoxicillin for 7 and 10 days were 66.7% (16/24), 89.2% (33/37), 81.0% (17/21), and 81.1% (30/37) (p = .191) by intention-to-treat analysis, respectively, and 72.7% (16/22), 89.2% (33/37), 81.0% (17/21), and 81.1% (30/37) (p = .454) by per-protocol analysis, respectively. Conclusion Neither 7- or 10-day VA dual therapy with b.i.d. or t.i.d. amoxicillin provides satisfied efficacy as the first-line treatment for H. pyloriinfection in China. Further optimization is needed. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

JGI at 25: The Human Genome Project, or the JGI’s Origin Story

alexandrossfakianakis shared this article with you from Inoreader JGI at 25: The Human Genome Project, or the JGI's Origin Story Via DOE Joint Genome Institute JGI at 25 revisits our contributions to the Human Genome Project, and our origins in DOE bringing together the people and resources from three national labs. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Effect of obesity on the associations of 25-hydroxyvitamin D with prevalent and incident distal sensorimotor polyneuropathy: population-based KORA F4/FF4 study

alexandrossfakianakis shared this article with you from Inoreader Effect of obesity on the associations of 25-hydroxyvitamin D with prevalent and incident distal sensorimotor polyneuropathy: population-based KORA F4/FF4 study Via International Journal of Obesity - Issue - nature.com science feeds View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Development of a targeted gene panel for the diagnosis of Gorlin syndrome

alexandrossfakianakis shared this article with you from Inoreader Message: A rare, inherited disorder that affects many organs and tissues in the body. People with this disorder have a very high risk of developing basal cell skin cancer during adolescence or early adulthood. They are also at risk of developing medulloblastoma (a type of brain cancer) and other types of cancer. Development of a targeted gene panel for the diagnosis of Gorlin syndrome Via International Journal of Oral and Maxillofacial Surgery via MedWorm.com In this study, a gene panel was developed to overcome the challenges in the diagnosis of Gorlin syndrome and allow diagnosis using a single test. A custom panel was generated for four genes associated with Gorlin syndrome: PTCH1, PTCH2, SMO, and SUFU. Twenty-seven samples from 12 patients with Gorlin syndrome and three asymptomatic blood relatives of the patients were examined. (Source: International Journal of Oral and Maxillofacial Surgery) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Epicardial adipose tissue in coronary microvascular dysfunction

alexandrossfakianakis shared this article with you from Inoreader Epicardial adipose tissue in coronary microvascular dysfunction Via International Journal of Obesity - Issue - nature.com science feeds International Journal of Obesity, Published online: 25 April 2022; doi:10.1038/s41366-022-01125-z Epicardial adipose tissue in coronary microvascular dysfunction View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States

alexandrossfakianakis shared this article with you from Inoreader Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States Via Neuro-Oncology Advance Access Abstract Background Selected molecular biomarkers were incorporated into U.S. cancer registry reporting for patients with brain tumors beginning in 2018. We investigated the completeness and validity of these variables, and described the epidemiology of molecularly-defined brain tumor types. Methods Brain tumor patients with histopathologically-confirmed diagnosis in 2018 were identified within the Central Brain Tumor Registry of the United States and NCI's Surveillance, Epidemiology, and End Results Incidence databases. The brain molecular markers (BMM) site-specific data item was assessed for coding completeness and validity. 1p/19q status, MGMT promoter methylation, and WHO grade data items, and new ICD-O-3 codes were additionally evaluated. These data were used to profile the characteristics and age-adjusted incidence rates per 100,000 population of molecularly-defined brain tumors with 95% confidence intervals (95%CI). Results BMM completeness across the applicable tumor types was 75-92% and demonstrated favorable coding validity. IDH-wildtype glioblastomas' incidence rate was 1.74 (95%CI: 1.69-1.78), as compared to 0.14 for WHO grade 2 (95%CI: 0.12-0.15), 0.15 for grade 3 (95%CI: 0.14-0.16), and 0.07 for grade 4 (95%CI: 0.06-0.08) IDH-mutant astrocytomas. Irrespective of WHO grade, IDH mutation prevalence was highest in adolescent & young adult patients and IDH-mutant astrocytomas were more frequently MGMT promoter methylated. Among pediatric-type tumors, the incidence rate was 0.06 for H3K27M-mutant diffuse midline gliomas (95%CI: 0.05-0.07), 0.03 for SHH-activated/TP53-wildtype medulloblastomas (95%CI: 0.02-0.03), and <0.01 for both C19MC-altered ETMRs and RELA-fusion ependymomas. Conclusions Our findings illustrate the success of developing a dedicated, integrated-diagnosis variable, which provides critical molecular information about brain tumors related to accurate diagnosis. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.